Lab Diagnostics Mobile to Take German Biotech Startup Deteczine Pocket € 3.2 Million

DeteczineA colon-based biotech startup, successfully collected € 3.2 million in its second seed round because it followed by mocking molecular diagnostics quickly, mobile and accessible to all.

The round was led by Newotech Ventures, NRW Bank, Acorius Invest, Mirkat Holding, Campus Capital and several strategic business angels.

“We are very grateful to our investors for their confidence in our team and our technology. Together, we turn into the future of diagnostics-more decentralized and more user-friendly” Dr. Reza EsmiliManaging Director of Deteczine.

The University Hospital, founded in 2022 by Dr. Reza Esmili and Dr. Robin Bayer, is developing deteczine, as a spin -off of Nepholab II ‘To go to PCR’A mobile molecular diagnostics platform that brings the laboratory test accuracy in the field.

Their pocket-size diagnostic device detects viruses, bacteria and fungus below 30 minutes, aiming that the PCR technology is combined with the ease of antigen examination. No expert equipment is needed, which means that testing can be somewhere-from GP practice to global resource-equipped healthcare settings.

BJ ParkManaging Partner, Neotch Ventures says, “Detekgine is facing a global challenge with a quick, mobile and specific solution – the laboratory does not compromise on the diagnostics standards. What has fascinated us is not just technology, but the power to execute the party. We are proud to support this type of diptech innovation coming out of the colon.“

The fresh capital will increase the mission of Detekgen to commercialize and produce its platform, not only in the German healthcare market, but also international deployment as well as sights.

Technology promises major impacts for healthcare systems, especially they are facing increasingly pressure to provide expensive, expensive diagnostic solutions, which maintains accuracy and high quality of speed.

Dr. Christophe Labis (Managing Director, Aquius Invest GMBH) added: “The successful completion of this finishing round sends a strong signal: detectures are bringing molecular diagnostics to where needed – fast, accurately and moving. The team not only provides great technology, but also shows the ability to scale. We are delighted to be part of this development in Aquius InvestThe “

NRW Bank, which has supported Detekzine since 2021 through initiatives like NRWSEDCON and NRWSEDCAP, also supports more than € 600K.

“” Startups in the healthcare sector are not only required scientific superiority, but also reliable financing, “ Explanation Johanna Antoni Tajaden-ShultA member of the Board of Directors of Management in the NRW Bank.

Since the public health system fights the deficiencies of worldwide employees, diagnostic barriers and decentralization claims, such as point -off care technology Will go to the PCR May take the role of a converter. The startup does not notice the advanced results of the patient only through primary, accurate diagnosis, but also reduce the cost and improve the infection control by providing the results when they need it.